Concord Wealth Partners Agios Pharmaceuticals, Inc. Transaction History
Concord Wealth Partners
- $710 Million
- Q3 2025
A detailed history of Concord Wealth Partners transactions in Agios Pharmaceuticals, Inc. stock. As of the latest transaction made, Concord Wealth Partners holds 200 shares of AGIO stock, worth $8,772. This represents 0.0% of its overall portfolio holdings.
Number of Shares
200
Previous 200
-0.0%
Holding current value
$8,772
Previous $6,000
33.33%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding AGIO
# of Institutions
243Shares Held
60.9MCall Options Held
297KPut Options Held
235K-
Farallon Capital Management LLC San Francisco, CA5.77MShares$253 Million0.86% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.6MShares$246 Million0.0% of portfolio
-
Black Rock Inc. New York, NY4.86MShares$213 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V83.59MShares$157 Million2.72% of portfolio
-
Erste Asset Management Gmb H Vienna, C42.76MShares$121 Million1.05% of portfolio
About AGIOS PHARMACEUTICALS, INC.
- Ticker AGIO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 54,818,000
- Market Cap $2.4B
- Description
- Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and ...